Tag Archives: brain cancer

November, 2018

16 November
Agios Presents Updated Data from Phase 1 Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma

NEW ORLEANS, Nov. 16, 2018 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today presented updated data from the ongoing Phase 1 study evaluating single agent AG-881 in advanced glioma. The data were featured in an …
Share

21 September
St. Jude Children’s Research Hospital and Tessa Therapeutics Collaborate to Develop Novel Therapies for Brain Cancer

MEMPHIS, Tenn. and SINGAPORE, Sept. 20, 2018 /PRNewswire/ — St. Jude Children’s Research Hospital (St. Jude), the U.S. hospital leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases, together with Tessa Therapeutics (Tessa), a clinical stage biopharmaceutical company, today announced the establishment of a …
Share

7 December
FDA Grants Full Approval for Genentech’s Avastin for the Treatment of Glioblastoma

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted full approval for Avastin®(bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy (referred to as recurrent disease). Avastin …
Share

4 August
Brain Tumor Scientists Map Mutation that Drives Tumors in Childhood Cancer Survivors

(TORONTO, Canada – Aug. 4, 2017) – Neuroscientists have uncovered the genetic basis for why many long-term survivors of childhood cancer develop meningiomas, the most common adult brain tumor, decades after their treatment with cranial radiation. The findings, published online today in Nature Communications, show that radiation causes genetic rearrangements in …
Share

8 May
Regeneron and Inovio Enter Agreement for Glioblastoma Combination Therapy

TARRYTOWN, N.Y. and PLYMOUTH MEETING, Pa., May 8, 2017 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced a clinical study agreement for a Phase 1b/2a immuno-oncology trial. The study will be conducted by Inovio in patients with newly-diagnosed glioblastoma multiforme (GBM) and will …
Share

27 March
Ziopharm Announces Successful End-of-Phase 2 Meeting with FDA for its Gene Therapy in Recurrent Glioblastoma

BOSTON, March 27, 2017 (GLOBE NEWSWIRE) — ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced the receipt of positive guidance from an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for its lead gene therapy product candidate, Ad-RTS-hIL-12 plus orally administered veledimex …
Share

24 February
Tocagen’s Lead Drug Candidate Receives Breakthrough Therapy from the FDA for Treatment of Recurrent High Grade Glioma

SAN DIEGO – Feb. 23, 2017 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced the U.S. Food and Drug Administration (FDA) has granted Toca 511 & Toca FC Breakthrough Therapy Designation for the treatment of patients with recurrent high grade glioma (HGG). Toca 511 & Toca FC …
Share
7 February
GW Pharma’s Cannabis-Derived Drug Shows Promise in Brain Cancer Study

London, UK, 7 Feb 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced positive top-line results from an exploratory Phase 2 placebo-controlled clinical study of a proprietary combination …
Share

25 January
Researchers Discover Potential New Target for Treating Glioblastoma

DALLAS – January 24, 2017 – Scientists have found a way to inhibit the growth of glioblastoma, a type of brain cancer with low survival rates, by targeting a protein that drives growth of brain tumors, according to research from the Peter O’Donnell Jr. Brain Institute and Harold C. Simmons …
Share

7 December
Researchers Find New Biomarker for Brain Cancer Prognosis

DALLAS – Dec. 6, 2016 – Researchers at UT Southwestern Medical Center have found a new biomarker for glioma, a common type of brain cancer, that can help doctors determine how aggressive a cancer is and that could eventually help determine the best course of treatment. Researchers from the Harold …
Share

Page 1 of 312 3 »